Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Withdrawn · Phase 2 · NCT06598631
Conditions: Chronic Kidney Disease
At a glance
- Research payments reported, 2025
- $131,038
- U.S. investigators named
- 9
- Sites paid
- 8
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Volenrelaxin (drug), Placebo (drug)
- Dates
- Started 2024-10; completion 2024-12
- Results posted
- Not yet
The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 24 weeks.
From ClinicalTrials.gov, last updated 2026-09-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $131,038 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nina A. Patel, M.D. Nephrology (Kidney) · Phoenix, AZ
- Tuan-huy V. Tran, MD Endocrinology & Diabetes · Metairie, LA
- Rekha E. John, M.D. Nephrology (Kidney) · Kinston, NC
- Eric A. Kirk, M.D. Nephrology (Kidney) · Wilmington, NC
- Kathryn J. Lucas, MD Endocrinology & Diabetes · Morehead City, NC
- Manuel Montero, M.D. Nephrology (Kidney) · New Bern, NC
- Nauman Shahid, M.D, Nephrology (Kidney) · Greenville, NC
- Koithara Varkey Thomas, M.D. Nephrology (Kidney) · Jacksonville, NC
- Gerardo Bueso, MD Endocrinology & Diabetes · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Eastern Nephrology Associates PLLC $79,438
- Omega Clinical Research LLC DBA Tuan Huy Tran $23,683
- Endocrine Associates $12,293
- Lucas Research Inc $8,942
- Rancho Research Institute $4,292
- Cleveland Clinic, OH $1,200
- $689
- Diabetes and Metabolism Associates, Apmc $330
- Diabetes and Endocrinology Consultants $171
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.